Changes in prostate apparent diffusion coefficient values during radiotherapy after neoadjuvant hormones
AuthorsMcPartlin, Andrew J
van Herk, Marcel
AffiliationThe Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
MetadataShow full item record
AbstractBACKGROUND: Changes in prostate cancer apparent diffusion coefficient (ADC) derived from diffusion-weighted magnetic resonance imaging (MRI) provide a noninvasive method for assessing radiotherapy response. This may be attenuated by neoadjuvant hormone therapy (NA-HT). We investigate ADC values measured before, during and after external beam radiotherapy (EBRT) following NA-HT. METHODS: Patients with ?T2c biopsy-proven prostate cancer receiving 3 months of NA-HT plus definitive radiotherapy were prospectively identified. All underwent ADC-MRI scans in the week before EBRT, in the third week of EBRT and 8 weeks after its completion. Imaging was performed at 1.5?T. The tumour, peripheral zone (PZ) and central zone (CZ) of the prostate gland were identified and median ADC calculated for each region and time point. RESULTS: Between September and December 2014, 15 patients were enrolled (median age 68.3, range 57-78) with a median Gleason score of 7 (6-9) and prostate-specific antigen (PSA) at diagnosis 14 (3-197) ng/ml. Median period of NA-HT prior to first imaging was 96 days (69-115). All patients completed treatment. Median follow up was 25 months (7-34), with one patient relapsing in this time. Thirteen patients completed all imaging as intended, one withdrew after one scan and another missed the final imaging. PZ and CZ could not be identified in one patient. Median tumour ADC before, during and post radiotherapy was 1.24?×?10-3?mm2/s (interquartile range 0.16?×?10-3?mm2/s), 1.31?×?10-3?mm2/s (0.22?×?10-3?mm2/s), then 1.32?×?10-3?mm2/s (0.13?×?10-3?mm2/s) respectively (p?>?0.05). There was no significant difference between median tumour and PZ or CZ ADC at any point. Gleason score did not correlate with ADC values. CONCLUSIONS: Differences in ADC parameters of normal and malignant tissue during EBRT appear attenuated by prior NA-HT. The use of changes in ADC as a predictive tool in this group may have limited utility.
CitationMcPartlin A, Kershaw L, McWilliam A, Taylor MB, Hodgson C, van Herk M, et al. Changes in prostate apparent diffusion coefficient values during radiotherapy after neoadjuvant hormones. Ther Adv Urol. 2018 Dec;10(12):359-64.
JournalTherapeutic Advances in Urology
- Apparent Diffusion Coefficient Values of the Benign Central Zone of the Prostate: Comparison With Low- and High-Grade Prostate Cancer.
- Authors: Gupta RT, Kauffman CR, Garcia-Reyes K, Palmeri ML, Madden JF, Polascik TJ, Rosenkrantz AB
- Issue date: 2015 Aug
- Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T.
- Authors: Song I, Kim CK, Park BK, Park W
- Issue date: 2010 Jun
- Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
- Authors: Roethke MC, Kuder TA, Kuru TH, Fenchel M, Hadaschik BA, Laun FB, Schlemmer HP, Stieltjes B
- Issue date: 2015 Aug
- Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer.
- Authors: Park SY, Kim CK, Park BK, Park W, Park HC, Han DH, Kim B
- Issue date: 2012 Jun 1
- Differentiation of prostate cancer lesions in the Transition Zone by diffusion-weighted MRI.
- Authors: Bao J, Wang X, Hu C, Hou J, Dong F, Guo L
- Issue date: 2017